Revolution Medicines (RVMD) is pushing forward with the commercial launch of daraxonrasib, branded as Rasonque, following a landmark approval from the US Food and Drug Administration.
The drug represents a historic milestone in oncology, becoming the first RAS inhibitor approved to treat pancreatic adenocarcinoma, the most common form of pancreatic cancer.
RAS mutations are responsible for nearly a third of all human cancers, yet scientists spent decades failing to develop effective drugs targeting the protein group.
The challenge stemmed from the protein’s unusually flat shape, which resisted conventional drug design approaches that had worked elsewhere in oncology research.
Revolution Medicines overcame that obstacle by engineering a novel molecular glue that latches onto a specific pocket on the RAS protein, disrupting its cancer-driving activity.
In a final-stage clinical trial published in May, daraxonrasib nearly doubled typical survival time for patients to 13.2 months, compared with 6.7 months for patients who received chemotherapy.
That survival improvement has been widely described as a transformative result in a disease notorious for its poor prognosis and limited treatment options.
Revolution Medicines has set a list price of $39,800 for a 30-day supply of Rasonque, and the company confirmed the drug is now commercially available in the United States.
In its second quarter 2026 financial results report, the company said it has been preparing for a commercial launch of the drug in the US and around the world.
The launch marks the culmination of years of research into RAS-targeted therapies and positions Revolution Medicines as a significant new force in the cancer treatment market.
Despite the scientific achievement, questions are circulating about the practical realities of bringing a drug at that price point to patients across the US healthcare system.
Access, reimbursement, and uptake among oncologists will be closely watched as the company transitions from clinical success to commercial execution in the months ahead.